Treasury Biotech Proposal Raises Questions, but No Procurement Details Are Available
The U.S. Department of the Treasury has put forward a biotech deal proposal that an anonymous industry lobbyist described as an escalation of policy, prompting uncertainty among pharmaceutical stakeholders. The available report provides no terms, funding, timeline, or purchasing action, so it does not establish a government contracting opportunity or new contractor requirement.